glimepiride has been researched along with Aging in 3 studies
glimepiride: structure given in first source
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Safety endpoints were adverse events including hypoglycaemia." | 2.84 | Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START-J trial). ( Ishida, H; Kitaoka, M; Ohsugi, M; Satoh, J; Seino, Y; Shihara, N; Terauchi, Y; Yabe, D; Yamada, Y, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Lietzau, G | 1 |
| Magni, G | 1 |
| Kehr, J | 1 |
| Yoshitake, T | 1 |
| Candeias, E | 1 |
| Duarte, AI | 1 |
| Pettersson, H | 1 |
| Skogsberg, J | 1 |
| Abbracchio, MP | 1 |
| Klein, T | 1 |
| Nyström, T | 1 |
| Ceruti, S | 1 |
| Darsalia, V | 1 |
| Patrone, C | 1 |
| Terauchi, Y | 1 |
| Yamada, Y | 1 |
| Ishida, H | 1 |
| Ohsugi, M | 1 |
| Kitaoka, M | 1 |
| Satoh, J | 1 |
| Yabe, D | 1 |
| Shihara, N | 1 |
| Seino, Y | 1 |
| Maeda, T | 1 |
| Oyama, J | 1 |
| Higuchi, Y | 1 |
| Koyanagi, M | 1 |
| Sasaki, M | 1 |
| Arima, T | 1 |
| Mimori, K | 1 |
| Makino, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety Comparison of Sitagliptin and Glimepiride in Elderly Japanese Patients With Type 2 Diabetes[NCT01183104] | 305 participants (Actual) | Interventional | 2010-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01183104)
Timeframe: Baseline and 52 W
| Intervention | kg (Mean) |
|---|---|
| Sitagliptin | -0.367 |
| Glimepiride | 0.309 |
(NCT01183104)
Timeframe: Baseline and 52 W
| Intervention | percent (Least Squares Mean) |
|---|---|
| Sitagliptin | -0.66 |
| Glimepiride | -0.77 |
β cell function is measured by the Homeostatic Model Assessment(HOMA-β). HOMA β = [20 x fasting insulin (μU/mL)] / [fasting plasma glucose (mmol/L) - 3.5] (NCT01183104)
Timeframe: Baseline and 52 W
| Intervention | percent (Mean) |
|---|---|
| Sitagliptin | 10.2 |
| Glimepiride | 23.7 |
(NCT01183104)
Timeframe: Baseline and 52 W
| Intervention | ratio (Mean) |
|---|---|
| Sitagliptin | -0.049 |
| Glimepiride | -0.002 |
(NCT01183104)
Timeframe: From baseline to 52 W
| Intervention | Participants (Count of Participants) |
|---|---|
| Sitagliptin | 7 |
| Glimepiride | 23 |
(NCT01183104)
Timeframe: 52 W
| Intervention | Participants (Count of Participants) |
|---|---|
| Sitagliptin | 89 |
| Glimepiride | 86 |
1 trial available for glimepiride and Aging
| Article | Year |
|---|---|
Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START-J trial).
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Aging; Blood Glucose Self-Monitoring; Diabetes | 2017 |
2 other studies available for glimepiride and Aging
| Article | Year |
|---|---|
Dipeptidyl peptidase-4 inhibitors and sulfonylureas prevent the progressive impairment of the nigrostriatal dopaminergic system induced by diabetes during aging.
Topics: Aging; Animals; Corpus Striatum; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dise | 2020 |
The correlation between clinical laboratory data and telomeric status of male patients with metabolic disorders and no clinical history of vascular events.
Topics: Aged; Aged, 80 and over; Aging; Bilirubin; Clinical Laboratory Techniques; Creatine Kinase; Diabetes | 2011 |